CY1124706T1 - Συνδυασμοι και χρησεις αυτων - Google Patents
Συνδυασμοι και χρησεις αυτωνInfo
- Publication number
- CY1124706T1 CY1124706T1 CY20211100817T CY211100817T CY1124706T1 CY 1124706 T1 CY1124706 T1 CY 1124706T1 CY 20211100817 T CY20211100817 T CY 20211100817T CY 211100817 T CY211100817 T CY 211100817T CY 1124706 T1 CY1124706 T1 CY 1124706T1
- Authority
- CY
- Cyprus
- Prior art keywords
- combinations
- phosphoinositide
- hodgkin
- lymphoma
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15181925 | 2015-08-21 | ||
| PCT/EP2016/069571 WO2017032679A1 (en) | 2015-08-21 | 2016-08-18 | Combinations and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124706T1 true CY1124706T1 (el) | 2022-07-22 |
Family
ID=54010888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100817T CY1124706T1 (el) | 2015-08-21 | 2021-09-17 | Συνδυασμοι και χρησεις αυτων |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US11224654B2 (https=) |
| EP (2) | EP3954388A1 (https=) |
| JP (4) | JP6862422B2 (https=) |
| KR (2) | KR102786010B1 (https=) |
| CN (2) | CN107921129B (https=) |
| AU (3) | AU2016311136B2 (https=) |
| CA (1) | CA2995738A1 (https=) |
| CY (1) | CY1124706T1 (https=) |
| DK (1) | DK3337506T3 (https=) |
| ES (1) | ES2891336T3 (https=) |
| HR (1) | HRP20211291T1 (https=) |
| HU (1) | HUE056408T2 (https=) |
| IL (2) | IL257345B2 (https=) |
| LT (1) | LT3337506T (https=) |
| MX (2) | MX392561B (https=) |
| PL (1) | PL3337506T3 (https=) |
| PT (1) | PT3337506T (https=) |
| RS (1) | RS62260B1 (https=) |
| RU (1) | RU2767063C2 (https=) |
| SI (1) | SI3337506T1 (https=) |
| SM (1) | SMT202100541T1 (https=) |
| WO (1) | WO2017032679A1 (https=) |
| ZA (1) | ZA201801052B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202100541T1 (it) * | 2015-08-21 | 2021-11-12 | Morphosys Ag | Combinazioni e loro usi |
| IL301786B2 (en) | 2016-10-28 | 2025-09-01 | Morphosys Ag | Combination of anti-CD19 antibody with BCL-2 inhibitor and their uses |
| HRP20231229T1 (hr) | 2017-05-31 | 2024-02-02 | Morphosys Ag | Paradigma liječenja za protutijelo anti-cd19 i venetoklaks kombinacijsko liječenje |
| WO2019011918A1 (en) | 2017-07-10 | 2019-01-17 | International - Drug - Development - Biotech | TREATMENT OF LYMPHOCYTE B MALIGNANCIES USING AFUCOSYLATED PRO-APOPTOTIC ANTI-CD19 ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES OR CHEMOTHERAPEUTIC AGENTS |
| KR20200030337A (ko) * | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| EP4051317A1 (en) * | 2019-10-31 | 2022-09-07 | MorphoSys AG | Sequential anti-cd19 therapy |
| CA3203587A1 (en) * | 2020-11-30 | 2022-06-02 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
| TW202334231A (zh) * | 2021-12-22 | 2023-09-01 | 德商莫菲西斯公司 | 抗cd19抗體療法的治療範例 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
| ES2788383T3 (es) | 2000-04-25 | 2020-10-21 | Icos Corp | Inhibidores de delta fosfatidilo-inositol 3-quinasa humana |
| CA2422076A1 (en) | 2000-09-18 | 2002-03-21 | Idec Pharmaceutical Corporation | Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| CA2467633C (en) | 2001-12-03 | 2012-03-27 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
| US20080152649A1 (en) * | 2002-03-01 | 2008-06-26 | Xencor, Inc. | Optimized igf-1r antibodies and methods of using the same |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| EP2216342B1 (en) | 2003-07-31 | 2015-04-22 | Immunomedics, Inc. | Anti-CD19 antibodies |
| SI2612862T1 (sl) | 2004-05-13 | 2017-04-26 | Icos Corporation | Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta |
| WO2007002223A2 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
| AU2006332155B2 (en) | 2005-12-30 | 2013-01-10 | Cancer Research Technology Limited | Anti-CD19 antibodies with reduced immunogenicity |
| PL2383297T3 (pl) * | 2006-08-14 | 2013-06-28 | Xencor Inc | Zoptymalizowane przeciwciała ukierunkowane na CD19 |
| KR101456728B1 (ko) | 2006-09-08 | 2014-10-31 | 메디뮨 엘엘씨 | 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도 |
| CA2693053C (en) | 2007-05-30 | 2021-01-05 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| RU2476441C2 (ru) | 2007-10-19 | 2013-02-27 | Сиэтл Дженетикс, Инк. | Cd19-связывающие средства и их применение |
| EP2398829A2 (en) | 2009-02-23 | 2011-12-28 | Glenmark Pharmaceuticals S.A. | Humanized antibodies that bind to cd19 and their uses |
| EP2445530B1 (en) | 2009-06-24 | 2016-09-07 | The Feinstein Institute for Medical Research | Method for treating chronic lymphocytic leukemia |
| CN107227335A (zh) * | 2009-10-27 | 2017-10-03 | 安进研发（慕尼黑）股份有限公司 | 用于施用CD19xCD3双特异性抗体的给药方案 |
| WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
| EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
| EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
| AU2011316917B2 (en) * | 2010-10-22 | 2016-02-25 | Seagen Inc. | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway |
| EP2524929A1 (en) | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| HUE058855T2 (hu) | 2011-08-16 | 2022-09-28 | Morphosys Ag | Kombinációs terápia, CD19 elleni ellenanyag és purinanalóg alkalmazásával |
| PL2744515T3 (pl) | 2011-08-16 | 2022-05-30 | Morphosys Ag | Terapia skojarzona przeciwciałem anty-cd19 i iperytem azotowym |
| SI2834241T1 (sl) | 2012-03-05 | 2021-06-30 | Gilead Calistoga Llc | Polimorfne oblike (S)-2-(1-(9H-purin-6-ilamino)propil)-5-fluoro-3-fenilkinazolin-4(3H)-ONA |
| EP2914296B2 (en) | 2012-11-01 | 2021-09-29 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| CA2900658A1 (en) | 2013-02-15 | 2014-08-21 | 3M Innovative Properties Company | System and method for making pleated filter media |
| JP2017519757A (ja) | 2014-06-16 | 2017-07-20 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | 慢性リンパ球性白血病（ｃｌｌ）の処置 |
| LT3302550T (lt) | 2015-05-26 | 2019-11-11 | Morphosys Ag | Anti-cd19 antikūno ir brutono tirozino kinazės inhibitoriaus derinys ir jo naudojimas |
| SMT202100541T1 (it) | 2015-08-21 | 2021-11-12 | Morphosys Ag | Combinazioni e loro usi |
| RS62155B1 (sr) | 2016-05-30 | 2021-08-31 | Morphosys Ag | Postupci predviđanja terapijske koristi anti-cd19 terapije kod pacijenata |
| SI3475303T1 (sl) | 2016-06-27 | 2021-12-31 | Morphosys Ag | Formulacija protitelesa proti CD19 |
| IL301786B2 (en) | 2016-10-28 | 2025-09-01 | Morphosys Ag | Combination of anti-CD19 antibody with BCL-2 inhibitor and their uses |
| HRP20231229T1 (hr) | 2017-05-31 | 2024-02-02 | Morphosys Ag | Paradigma liječenja za protutijelo anti-cd19 i venetoklaks kombinacijsko liječenje |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| MX2021013101A (es) | 2019-05-03 | 2022-01-04 | Morphosys Ag | Terapia anti-cd19 en pacientes que tienen una cantidad limitada de células nk. |
| TWI865644B (zh) | 2019-10-31 | 2024-12-11 | 德商莫菲西斯公司 | 用於治療白血病或淋巴瘤之抗cd19療法與來那度胺(lenalidomide)的組合 |
| EP4051317A1 (en) | 2019-10-31 | 2022-09-07 | MorphoSys AG | Sequential anti-cd19 therapy |
| US20210130461A1 (en) | 2019-10-31 | 2021-05-06 | Morphosys Ag | Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells |
| US20230014026A1 (en) | 2020-06-22 | 2023-01-19 | Morphosys Ag | Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint |
| CA3203587A1 (en) | 2020-11-30 | 2022-06-02 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
| US20220184208A1 (en) | 2020-12-04 | 2022-06-16 | Morphosys Ag | Anti-cd19 combination therapy |
| TW202334231A (zh) | 2021-12-22 | 2023-09-01 | 德商莫菲西斯公司 | 抗cd19抗體療法的治療範例 |
-
2016
- 2016-08-18 SM SM20210541T patent/SMT202100541T1/it unknown
- 2016-08-18 HU HUE16756997A patent/HUE056408T2/hu unknown
- 2016-08-18 IL IL257345A patent/IL257345B2/en unknown
- 2016-08-18 AU AU2016311136A patent/AU2016311136B2/en active Active
- 2016-08-18 HR HRP20211291TT patent/HRP20211291T1/hr unknown
- 2016-08-18 CN CN201680048061.2A patent/CN107921129B/zh active Active
- 2016-08-18 LT LTEPPCT/EP2016/069571T patent/LT3337506T/lt unknown
- 2016-08-18 IL IL297057A patent/IL297057B2/en unknown
- 2016-08-18 RU RU2018107929A patent/RU2767063C2/ru active
- 2016-08-18 ES ES16756997T patent/ES2891336T3/es active Active
- 2016-08-18 PT PT167569979T patent/PT3337506T/pt unknown
- 2016-08-18 US US15/752,009 patent/US11224654B2/en active Active
- 2016-08-18 EP EP21186316.2A patent/EP3954388A1/en active Pending
- 2016-08-18 RS RS20211009A patent/RS62260B1/sr unknown
- 2016-08-18 EP EP16756997.9A patent/EP3337506B1/en active Active
- 2016-08-18 SI SI201631293T patent/SI3337506T1/sl unknown
- 2016-08-18 CN CN202210502807.XA patent/CN115054697B/zh active Active
- 2016-08-18 PL PL16756997T patent/PL3337506T3/pl unknown
- 2016-08-18 JP JP2018508728A patent/JP6862422B2/ja active Active
- 2016-08-18 DK DK16756997.9T patent/DK3337506T3/da active
- 2016-08-18 KR KR1020247011695A patent/KR102786010B1/ko active Active
- 2016-08-18 MX MX2018002241A patent/MX392561B/es unknown
- 2016-08-18 WO PCT/EP2016/069571 patent/WO2017032679A1/en not_active Ceased
- 2016-08-18 CA CA2995738A patent/CA2995738A1/en active Pending
- 2016-08-18 KR KR1020187007728A patent/KR20180042335A/ko not_active Ceased
-
2018
- 2018-02-15 ZA ZA2018/01052A patent/ZA201801052B/en unknown
- 2018-02-20 MX MX2022006154A patent/MX2022006154A/es unknown
-
2021
- 2021-03-31 JP JP2021059383A patent/JP2021113194A/ja active Pending
- 2021-09-17 CY CY20211100817T patent/CY1124706T1/el unknown
- 2021-12-08 US US17/545,274 patent/US12194095B2/en active Active
-
2022
- 2022-04-28 AU AU2022202800A patent/AU2022202800B2/en active Active
-
2023
- 2023-03-30 JP JP2023054891A patent/JP2023093495A/ja active Pending
-
2024
- 2024-04-02 AU AU2024202109A patent/AU2024202109A1/en not_active Abandoned
- 2024-12-02 US US18/965,167 patent/US20250195646A1/en active Pending
-
2025
- 2025-06-04 JP JP2025093012A patent/JP2025131697A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124706T1 (el) | Συνδυασμοι και χρησεις αυτων | |
| CY1122298T1 (el) | Συνδυασμος αντισωματος anτι-cd19 και αναστολεα τυροσινης κινασης toy bruton και χρησεις του | |
| CY1124648T1 (el) | Συνδυασμος αντισωματος αντι- cd19 με εναν αναστολεα bcl-2 και χρησεις αυτου | |
| CY1125588T1 (el) | Θεραπευτικοι συνδυασμοι ενος αναστολεα βτκ και ενος αναστολεα bcl-2 | |
| CY1124215T1 (el) | Μκ2 αναστολεις και χρησεις αυτων | |
| CY1122653T1 (el) | Αντισωματα αντι-τιgιτ, αντισωματα αντι-ρvrig και συνδυασμοι εξ αυτων | |
| CY1122510T1 (el) | Μορια αντισωματος σε lag-3 και χρησεις αυτων | |
| CY1125148T1 (el) | Θεραπεια συνδυασμου με αντι-cd19 αντισωμα και αναλογο πουρινης | |
| IL271266A (en) | Use of anti cd70 antibody argx-110 to treat acute myeloid leukaemia | |
| CL2019001554S1 (es) | Automóvil. | |
| CY1121806T1 (el) | Ιμιδαζοπυραζινονες ως αναστολεις pde1 | |
| TR201810635T4 (tr) | Anti-jagged1 antikorları ve kullanım yöntemleri. | |
| LT3661514T (lt) | Mavakamtenas, skirtas naudoti gydant hipertrofinę kardiomiopatiją | |
| CY1124338T1 (el) | Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων | |
| CY1125122T1 (el) | Θεραπεια συνδυασμου me anti-cd19 αντισωμα και μουσταρδα αζωτου | |
| BR112018001853A2 (pt) | métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio | |
| CY1120751T1 (el) | Αναστολεις ετεροδικυκλοαρυλιου του rorc2 και μεθοδοι χρησης αυτων | |
| CY1126725T1 (el) | Αλπραζολαμη για χρηση στη θεραπεια της επιληψιας | |
| EA201991818A1 (ru) | Лечение рака | |
| HUE056067T2 (hu) | Takrolimuszt tartalmazó nanorészecskék | |
| UY38352A (es) | Inhibidores de integrina alfavbeta6 | |
| CL2019000049A1 (es) | Procesos para la preparación de oxipicolinamidas 4 - alkoxi - (acil o aquil). | |
| CY1122784T1 (el) | Αλογονωμενες κιναζολιν-τηf-αμινες ως αναστολεις του ρdε1 | |
| IL282041A (en) | Egfr inhibitors for treating keratodermas | |
| CL2021001922A1 (es) | Procedimientos para tratamiento de enfermedades con inhibidores de magl. |